StockNews.AI
UNCY
StockNews.AI
16 hrs

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY

1. Class action lawsuit filed against Unicycive Therapeutics for misleading statements. 2. Accusations involve overly optimistic claims about FDA approval of OLC. 3. Shareholders from March 2024 to June 2025 can participate in recovery. 4. False public statements may have misled investors and impacted share value. 5. DJS Law Group specializes in securities class actions and investor advocacy.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit indicates potential long-term mismanagement and shareholder mistrust, likely driving down stock prices. Historical cases show similar lawsuits have negatively affected stock values post-announcement.

How important is it?

The class action highlights serious allegations of misleading investors, likely impacting stock performance significantly as it raises concerns about corporate governance and long-term viability.

Why Long Term?

As legal proceedings unfold, uncertainty can hinder investor confidence and company performance, affecting stock prices over an extended period.

Related Companies

ABUSSAVA
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of UNCY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  March 29, 2024 to June 27, 2025 DEADLINE: October 14, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Unicycive was overly optimistic about its chances for FDA approval of OLC, a treatment for hyperphosphatemia in CKD patients on dialysis. Based on these facts, Unicycive's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1  Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News